We also found that treatment with STA21, a STAT3 inhibitor, abrogated IL-17-induced Bcl-2 expression in FLSs from RA patients (Figure 3B), demonstrating that STAT3 is involved in IL-17-induced Bcl-2 expression. This evidence concerns the gene IL17A and rheumatoid arthritis.